SMMT
Another biotech cliffhanger, but with a happy ending
Summit Therapeutics got a fresh dose of investor attention after saying its drug ivonescimab, paired with chemotherapy, showed a statistically significant overall survival benefit in the HARMONi-6 study for first-line squamous NSCLC in China. In biotech land, that’s basically the difference between a maybe and a mic-drop.
Why this matters
Overall survival is the gold standard. It’s not just “the tumor shrank” or “the scans looked cute for a while” — it’s the one endpoint that can make a therapy feel real to doctors, regulators, and the market. For Summit, that matters because ivonescimab is the company's crown jewel, and every strong data point helps the bull case look less like hopium and more like a plan.
The market angle
The comparison here was against tislelizumab plus chemotherapy in squamous NSCLC, a brutally competitive corner of oncology where everyone is trying to build the better combo meal. If the survival benefit holds up in deeper analysis, Summit could have a stronger argument that ivonescimab deserves a seat at the big table in lung cancer.
Big picture
Biotech investors love two things: data and drama. This update delivers both. The catch, as always, is that one good readout is not a fairy-tale ending — it’s a checkpoint. But in a sector where many hopeful drugs quietly fade into the background, a statistically significant survival win is the kind of news that can keep the story very much alive.